Objective:
To compare guideline recommendations from the International Headache Society (IHS) and the American College of Physicians (ACP) regarding optimal acute and preventive treatment strategies for migraine.
Key Findings:
- IHS recommends triptans as first-line acute therapy; ACP suggests triptans combined with NSAIDs or acetaminophen.
- Triptans show higher efficacy than NSAIDs in achieving pain freedom at 2 hours, with specific odds ratios.
- Preventive therapy trials lack high-quality evidence, with no significant differences in efficacy among treatments.
- CGRP-targeting therapies may offer faster response but at a higher cost compared to traditional oral medications, with specific cost comparisons.
Interpretation:
Treatment strategies for migraine should be individualized, considering patient-specific factors and the differing recommendations from IHS and ACP, emphasizing the need for a patient-centered approach.
Limitations:
- Most studies on preventive therapies are placebo-controlled, limiting comparative evidence and generalizability.
- The APPRAISE trial's population may not be generalizable as it included only patients with prior treatment failure, which could skew results.
Conclusion:
A patient-centered approach is essential in migraine management, taking into account clinical variables, treatment history, and individual patient needs.
